OncoMatch/Clinical Trials/NCT03125642
Auto Stem Cell Transplant for Lymphoma Patients
Is NCT03125642 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments for non-hodgkin lymphoma.
Treatment: Etoposide · BCNU · AraC · Melphalan · G-CSF · Cyclophosphamide — This is a phase II study of autologous transplant for patients with Hodgkin (HL) and non-Hodgkin lymphomas (NHL) including those who are HIV positive.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Hodgkin Lymphoma
Hodgkin Lymphoma
Disease stage
Required: Stage I, II, III, IV
Prior therapy
Must have received: cell therapy
Patients in partial or complete remission following cell therapy will also be eligible.
Must have received: combination chemotherapy — salvage
For stage I/II patients treated with primary chemotherapy-radiation, they must have failed (no CR or progression after CR) at least one salvage combination chemotherapy treatment regimen
Must have received: Adriamycin containing regimen (ABVD) or alternative non-cross resistant regimen (e.g. MOPP) (ABVD, MOPP) — advanced Hodgkin disease
For advanced (stage III/IV) Hodgkin disease, patients must have failed an Adriamycin containing regimen (ABVD) or an alternative non-cross resistant regimen (e.g. MOPP)
Cannot have received: nitrosoureas
At least 6 weeks from nitrosoureas
Lab requirements
Blood counts
hemoglobin > 8 gm/dL; WBC > 2.5 x 10^9/L with an ANC > 1.5 x 10^9/L off G-CSF or GM-CSF for 10 days or Neulasta for 21 days; platelets > 100 x 10^9/L without transfusion; bone marrow cellularity of > 20% with <5% involvement with tumor
Kidney function
GFR > 50 ml/min/1.73m2 or serum creatinine ≤ 2.5 x ULN for age
Liver function
no history of severe prior or ongoing chronic liver disease. Total bilirubin ≤ 2.0 mg/dl, AST and alkaline phosphatase <5x upper limit of normal
Cardiac function
free of symptoms of uncontrolled cardiac disease including unstable angina, decompensated congestive heart failure, or arrhythmia. The ejection fraction by gated cardiac blood flow scan (MUGA) or Echocardiogram must be >40%
No evidence of serious organ dysfunction that is not attributable to tumor including: Hematologic: hemoglobin > 8 gm/dL, WBC > 2.5 x 10^9/L with an ANC > 1.5 x 10^9/L off G-CSF or GM-CSF for 10 days or Neulasta for 21 days, platelets > 100 x 10^9/L without transfusion, bone marrow cellularity of > 20% with <5% involvement with tumor; Renal: GFR > 50 ml/min/1.73m2 or serum creatinine ≤ 2.5 x ULN for age; Hepatic: no history of severe prior or ongoing chronic liver disease. Total bilirubin ≤ 2.0 mg/dl, AST and alkaline phosphatase <5x upper limit of normal; Cardiac: free of symptoms of uncontrolled cardiac disease including unstable angina, decompensated congestive heart failure, or arrhythmia. The ejection fraction by gated cardiac blood flow scan (MUGA) or Echocardiogram must be >40%; Pulmonary: no significant obstructive airways disease (FEV1 must be ≥ 50%) and must have acceptable diffusion capacity (corrected DLCO > 50% of predicted)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Masonic Cancer Center, University of Minnesota · Minneapolis, Minnesota
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify